

Ellen Heitzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6614111/publications.pdf>

Version: 2024-02-01

110
papers

6,843
citations

94433

37
h-index

64796

79
g-index

119
all docs

119
docs citations

119
times ranked

10715
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and future perspectives of liquid biopsies in genomics-driven oncology. <i>Nature Reviews Genetics</i> , 2019, 20, 71-88.	16.3	912
2	Circulating Tumor DNA as a Liquid Biopsy for Cancer. <i>Clinical Chemistry</i> , 2015, 61, 112-123.	3.2	654
3	Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing. <i>Cancer Research</i> , 2013, 73, 2965-2975.	0.9	497
4	Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. <i>Genome Medicine</i> , 2013, 5, 30.	8.2	306
5	Tubuloids derived from human adult kidney and urine for personalized disease modeling. <i>Nature Biotechnology</i> , 2019, 37, 303-313.	17.5	301
6	Inferring expressed genes by whole-genome sequencing of plasma DNA. <i>Nature Genetics</i> , 2016, 48, 1273-1278.	21.4	295
7	Hematogenous dissemination of glioblastoma multiforme. <i>Science Translational Medicine</i> , 2014, 6, 247ra101.	12.4	264
8	Circulating biomarkers for early detection and clinical management of colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019, 69, 107-122.	6.4	214
9	Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing. <i>PLoS Genetics</i> , 2014, 10, e1004271.	3.5	157
10	Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. <i>International Journal of Cancer</i> , 2013, 133, 346-356.	5.1	155
11	Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. <i>Trends in Molecular Medicine</i> , 2020, 26, 519-528.	6.7	151
12	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019, 10, 4666.	12.8	146
13	Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. <i>Nature Communications</i> , 2016, 7, 12008.	12.8	134
14	The potential of liquid biopsies for the early detection of cancer. <i>Npj Precision Oncology</i> , 2017, 1, 36.	5.4	126
15	Circulating tumor cells and DNA as liquid biopsies. <i>Genome Medicine</i> , 2013, 5, 73.	8.2	116
16	The dynamic range of circulating tumor DNA in metastatic breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 421.	5.0	113
17	Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative's Computerised Symptom Assessment study. <i>Palliative Medicine</i> , 2013, 27, 714-721.	3.1	111
18	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. <i>Clinical Chemistry</i> , 2020, 66, 149-160.	3.2	100

#	ARTICLE	IF	CITATIONS
19	Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. <i>Clinical Chemistry</i> , 2015, 61, 838-849.	3.2	94
20	Replicative DNA polymerase mutations in cancer. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 107-113.	3.3	92
21	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020, 12, 23.	8.2	66
22	miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. <i>Clinical Cancer Research</i> , 2017, 23, 5255-5266.	7.0	65
23	Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 516-523.	3.5	65
24	Noninvasive detection of genome-wide somatic copy number alterations by liquid biopsies. <i>Molecular Oncology</i> , 2016, 10, 494-502.	4.6	63
25	p14ARF Hypermethylation Is Common but INK4a-ARF Locus or p53 Mutations Are Rare in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1788-1796.	0.7	58
26	Computer-Based Symptom Assessment Is Feasible in Patients With Advanced Cancer: Results From an International Multicenter Study, the EPCRC-CSA. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 639-654.	1.2	54
27	Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100399.	4.5	54
28	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. <i>Nature Communications</i> , 2014, 5, 5191.	12.8	51
29	High Quality Assessment of DNA Methylation in Archival Tissues from Colorectal Cancer Patients Using Quantitative High-Resolution Melting Analysis. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 102-108.	2.8	50
30	Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling. <i>Cancers</i> , 2020, 12, 1588.	3.7	50
31	G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. <i>International Journal of Cancer</i> , 2018, 142, 121-132.	5.1	49
32	Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1070-1086.	2.8	48
33	Patient monitoring through liquid biopsies using circulating tumor DNA. <i>International Journal of Cancer</i> , 2017, 141, 887-896.	5.1	46
34	Single tube liquid biopsy for advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 3127-3137.	5.1	45
35	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2587-2591.	1.4	44
36	POLE mutations in families predisposed to cutaneous melanoma. <i>Familial Cancer</i> , 2015, 14, 621-628.	1.9	43

#	ARTICLE	IF	CITATIONS
37	Co-occurrence of MYC amplification and TP53 mutations in human cancer. <i>Nature Genetics</i> , 2016, 48, 104-106.	21.4	42
38	Functional Classification of TP53 Mutations in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 637.	3.7	42
39	Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors. <i>Modern Pathology</i> , 2016, 29, 1262-1277.	5.5	39
40	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. <i>International Journal of Cancer</i> , 2018, 143, 1236-1248.	5.1	37
41	UV Fingerprints Predominate in the PTCH Mutation Spectra of Basal Cell Carcinomas Independent of Clinical Phenotype. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2872-2881.	0.7	33
42	Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1540-1553.	3.0	33
43	Depressed patients with incurable cancer: Which depressive symptoms do they experience?. <i>Palliative and Supportive Care</i> , 2013, 11, 491-501.	1.0	31
44	Preexisting TP53 mutation in therapy-related acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 527-529.	1.8	27
45	Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. <i>Modern Pathology</i> , 2017, 30, 1698-1709.	5.5	27
46	One size does not fit all: Size-based plasma DNA diagnostics. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	27
47	Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition. <i>Scientific Reports</i> , 2017, 7, 10040.	3.3	26
48	Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. <i>ESMO Open</i> , 2020, 5, e000872.	4.5	26
49	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. <i>Genome Medicine</i> , 2020, 12, 20.	8.2	25
50	Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. <i>Clinical Chemistry</i> , 2019, 65, 462-472.	3.2	24
51	mFast-Seq as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 147-155.	1.6	23
52	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017, 80, 73-153.	3.7	23
53	PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches. <i>Experimental Dermatology</i> , 2010, 19, 926-928.	2.9	22
54	Genetic and epigenetic analysis of putative breast cancer stem cell models. <i>BMC Cancer</i> , 2013, 13, 358.	2.6	22

#	ARTICLE	IF	CITATIONS
55	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014, 27, 906-915.	5.5	21
56	The BRAF V600K Mutation Is More Frequent than the BRAF V600E Mutation in Melanoma In Situ of Lentigo Maligna Type. <i>Journal of Investigative Dermatology</i> , 2014, 134, 548-550.	0.7	21
57	Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment. <i>Cancers</i> , 2019, 11, 1171.	3.7	21
58	Rapid and reliable detection of LINE-1 hypomethylation using high-resolution melting analysis. <i>Clinical Biochemistry</i> , 2010, 43, 1443-1448.	1.9	20
59	Detection of Circulating Tumor DNA in the Blood of Cancer Patients: An Important Tool in Cancer Chemoprevention. <i>Methods in Molecular Biology</i> , 2016, 1379, 45-68.	0.9	19
60	A novel mutation in <i>ATRAX</i> associated with intellectual disability, syndromic features, and osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26522.	1.5	18
61	A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. <i>Cancers</i> , 2020, 12, 2247.	3.7	18
62	Cell-Free DNA Fragmentomics: The New "Omics" on the Block. <i>Clinical Chemistry</i> , 2020, 66, 1480-1484.	3.2	18
63	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	7.0	17
64	T1799A BRAF Mutation is Common in PUVA Lentigines. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1915-1917.	0.7	16
65	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 23-30.	4.1	16
66	Extra phenotypic features in a girl with Miller syndrome. <i>Clinical Dysmorphology</i> , 2011, 20, 66-72.	0.3	15
67	Single-Stranded DNA Library Preparation Does Not Preferentially Enrich Circulating Tumor DNA. <i>Clinical Chemistry</i> , 2017, 63, 1656-1659.	3.2	15
68	Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 456-463.	6.4	15
69	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 2798-2806.	7.0	14
70	Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies. <i>Scientific Reports</i> , 2016, 6, 24195.	3.3	13
71	On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. <i>Npj Precision Oncology</i> , 2020, 4, 30.	5.4	13
72	Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival. <i>Cancers</i> , 2020, 12, 1481.	3.7	13

#	ARTICLE	IF	CITATIONS
73	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. <i>American Journal of Hematology</i> , 2020, 95, 1148-1157.	4.1	13
74	Single circulating tumor cell sequencing for monitoring. <i>Oncotarget</i> , 2013, 4, 812-813.	1.8	13
75	Human melanoma brain metastases cell line MUG-Mel1, isolated clones and their detailed characterization. <i>Scientific Reports</i> , 2019, 9, 4096.	3.3	11
76	Novel phenotypes observed in patients with <i>ETV6</i> -linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor. <i>Journal of Medical Genetics</i> , 2020, 57, 427-433.	3.2	11
77	β -catenin regulates FOXP2 transcriptional activity via multiple binding sites. <i>FEBS Journal</i> , 2021, 288, 3261-3284.	4.7	11
78	MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line. <i>Scientific Reports</i> , 2017, 7, 2098.	3.3	10
79	Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor?. <i>Histochemistry and Cell Biology</i> , 2018, 150, 83-92.	1.7	10
80	A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. <i>International Journal of Cancer</i> , 2021, 148, 1452-1461.	5.1	10
81	IL-7, IL-18, MCP-1, MIP1- β , and OPG as biomarkers for pain treatment response in patients with cancer. <i>Pain Physician</i> , 2012, 15, 499-510.	0.4	9
82	Interviews with patients with advanced cancer—another step towards an international cancer pain classification system. <i>Supportive Care in Cancer</i> , 2012, 20, 2491-2500.	2.2	8
83	Expression of the cancer-associated DNA polymerase δ P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication. <i>PLoS Genetics</i> , 2021, 17, e1009526.	3.5	8
84	Infrequent p53 gene mutation but UV gradient-like p53 protein positivity in keloids. <i>Experimental Dermatology</i> , 2012, 21, 277-280.	2.9	7
85	Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR + breast cancer patients undergoing CDK4/6 treatment. <i>Molecular Oncology</i> , 2020, 15, 2390-2400.	4.6	7
86	Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients. <i>Biomolecules</i> , 2021, 11, 618.	4.0	7
87	Digital Circulating Tumor Cell Analyses for Prostate Cancer Precision Oncology. <i>Cancer Discovery</i> , 2018, 8, 269-271.	9.4	6
88	Point: Circulating Tumor DNA for Modern Cancer Management. <i>Clinical Chemistry</i> , 2020, 66, 143-145.	3.2	6
89	Genetic profiling of putative breast cancer stem cells from malignant pleural effusions. <i>PLoS ONE</i> , 2017, 12, e0175223.	2.5	6
90	Polyclonality of Multiple Sporadic Basal Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1586-1589.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Genome-Wide Analysis of the Nucleosome Landscape in Individuals with Coffin-Siris Syndrome. <i>Cytogenetic and Genome Research</i> , 2019, 159, 1-11.	1.1	5
92	TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model. <i>Annals of Hematology</i> , 2020, 99, 653-655.	1.8	5
93	Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma. <i>Scientific Reports</i> , 2021, 11, 12466.	3.3	5
94	Vocal Fold Fibroblasts in Reinke's Edema Show Alterations Involved in Extracellular Matrix Production, Cytokine Response and Cell Cycle Control. <i>Biomedicines</i> , 2021, 9, 735.	3.2	5
95	Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	3.2	5
96	Nonmonoclonal PTCH Gene Mutations in Psoralen Plus UVA-Associated Basal Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2008, 128, 746-749.	0.7	4
97	Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions. <i>Annals of Hematology</i> , 2019, 98, 2019-2020.	1.8	4
98	Untargeted profiling of cell-free circulating DNA. <i>Translational Cancer Research</i> , 2018, 7, S140-S152.	1.0	4
99	Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA. <i>Experimental and Molecular Pathology</i> , 2021, 123, 104685.	2.1	3
100	Molecular profiling of soft-tissue sarcomas with FoundationOne [®] Heme identifies potential targets for sarcoma therapy: a single-centre experience. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110291.	3.2	3
101	Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer. <i>Lung Cancer</i> , 2022, 170, 52-57.	2.0	3
102	Clinical utility of circulating tumor DNA in human cancers. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 222-226.	0.5	2
103	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
104	MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11318.	4.1	2
105	Depressed patients with incurable cancer: Which depressive symptoms do they experience?â€”ERRATUM. <i>Palliative and Supportive Care</i> , 2013, 11, 535-535.	1.0	1
106	Potentials, challenges and limitations of a molecular characterization of circulating tumor DNA for the management of cancer patients. <i>Laboratoriums Medizin</i> , 2016, 40, 323-334.	0.6	1
107	Functional Classification of TP53 Mutations in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2725-2725.	1.4	1
108	Academia Meets Industry. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 201-215.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Potential and Challenges of Liquid Biopsies. , 2017, , 233-261.		0
110	Characterisation and treatment of patients with castration-resistant metastatic prostate cancer (mCRPC) developing neuroendocrine clonal divergence (NCD): A case series.. Journal of Clinical Oncology, 2017, 35, e16520-e16520.	1.6	0